CareDx (CDNA) Rallies On Growth Optimism, Is It Still 10% Undervalued?

Simply Wall St.13:22

CareDx (CDNA) has drawn investor attention after a recent move in its share price, with the stock closing at $46.99. This shift is prompting fresh questions about how current performance lines up with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661257917?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-21 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661257917","market":"hk","top_or_hot":-1,"title":"CareDx (CDNA) Rallies On Growth Optimism, Is It Still 10% Undervalued?","media":"Simply Wall St.","content":"<div>\n<p>CareDx (CDNA) has drawn investor attention after a recent move in its share price, with the stock closing at $46.99. This shift is prompting fresh questions about how current performance lines up with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-rallies-on-growth-optimism-is-it-still-10-underv\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CareDx (CDNA) Rallies On Growth Optimism, Is It Still 10% Undervalued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCareDx (CDNA) Rallies On Growth Optimism, Is It Still 10% Undervalued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 13:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-rallies-on-growth-optimism-is-it-still-10-underv><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CareDx (CDNA) has drawn investor attention after a recent move in its share price, with the stock closing at $46.99. This shift is prompting fresh questions about how current performance lines up with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-rallies-on-growth-optimism-is-it-still-10-underv\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTHR","symbol_name":"Vanguard Russell 3000 ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-rallies-on-growth-optimism-is-it-still-10-underv","article_id":"2661257917","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-rallies-on-growth-optimism-is-it-still-10-underv","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661257917","pubTimestamp":1787289762,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CareDx (CDNA) has drawn investor attention after a recent move in its share price, with the stock closing at $46.99. This shift is prompting fresh questions about how current performance lines up with fundamentals.\nSee our latest analysis for CareDx.\nThe recent 1 day share price return of 1.03% to $46.99 comes after a strong 30 day share price return of 21.93% and a 90 day gain of 117.24%. The 1 year total shareholder return of 275.62% and 3 year total shareholder return of 439.49% point to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTHR":"Vanguard Russell 3000 ETF","BK4139":"生物科技","AIPO":"Defiance AI and Power Infrastructure ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AGIX":"通用人工智能 ETF-AGIX","ARTY":"ISHARES FUTURE AI & TECH ETF","BMED":"iShares Health Innovation Active ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October","CDNA":"CareDx"},"translate_title":"CareDx (CDNA) 因增长乐观情绪而反弹，但仍被低估 10%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHAT":0.61,"BMED":0.61,"AIPO":0.61,"ARTY":0.61,"CDNA":1.5,"AGIX":0.61,"QTOC":0.61,"VTHR":0.61},"content_text":"CareDx (CDNA) has drawn investor attention after a recent move in its share price, with the stock closing at $46.99. This shift is prompting fresh questions about how current performance lines up with fundamentals. See our latest analysis for CareDx. The recent 1 day share price return of 1.03% to $46.99 comes after a strong 30 day share price return of 21.93% and a 90 day gain of 117.24%. The 1 year total shareholder return of 275.62% and 3 year total shareholder return of 439.49% point to powerful momentum despite a weaker 5 year total shareholder return. This suggests sentiment around CareDx has shifted sharply as investors reassess its growth potential and risks. If the renewed interest in CareDx has you rethinking your watchlist, this could be a useful moment to look at other healthcare AI opportunities through the 40 healthcare AI stocks After a move like this, the real tension for CareDx investors is whether the major rerating has already played out or if the recent jump still leaves meaningful upside on the table. The valuation numbers offer some clues next. AdvertisementMost Popular Narrative: 10.2% Undervalued CareDx's most followed narrative places fair value at $52.33 a share, compared with the latest close at $46.99. This frames the recent rally in a different light and puts the focus on how long that valuation gap could persist.  The launch of AI-driven diagnostics like AlloSure Plus and integration into electronic health record systems (e.g., EPIC) positions CareDx to benefit from the broader adoption of precision medicine and personalized diagnostics, likely boosting adoption rates, aiding reimbursement, and ultimately supporting net margin improvements.  Read the complete narrative. Want to see what underpins that fair value for CareDx? The narrative leans on specific revenue growth, shrinking margins, and a future earnings multiple that most investors would not expect. Result: Fair Value of $52.33 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the CareDx narrative also hinges on sensitive Medicare reimbursement policies and smooth Naveris integration. Both of these factors could challenge the current valuation case. Find out about the key risks to this CareDx narrative. Another View on CareDx Valuation While the analyst narrative points to CareDx trading below a fair value of $52.33, the P/E ratios tell a different story. The current P/E of 21.9x is higher than the 17.8x US Biotechs industry average and far above a 6x fair ratio. This may signal meaningful valuation risk if sentiment cools. For investors, that gap between a 6x fair ratio, the 17.8x industry level, and CareDx at 21.9x raises a simple question: Is the market being too generous on the current earnings base, or is it correctly pricing in a much stronger long term story for this stock See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:CDNA P/E Ratio as at Aug 2026Next Steps Given the mixed sentiment around CareDx, this is a moment to review the numbers yourself and decide how you feel about its risk and reward balance. To see both sides laid out clearly, start with the 2 key rewards and 4 important warning signs Looking for more CareDx sized investment ideas? If you stop with CareDx, you risk missing other stocks that fit your style. Use the Simply Wall Street Screener to spot opportunities before they move.  Target potential mispricings by scanning 50 high quality undervalued stocks that pair quality fundamentals with more modest expectations. Prioritise resilience by checking 79 resilient stocks with low risk scores that score well on financial strength and business stability. Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems that are already posting strong fundamentals before they become widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661257917","isCrawlerRequest":true}